Search Results - "Soroko, Kara M"

Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734 by Morrison-Smith, Chevaun D, Knox, Tatiana M, Filic, Ivona, Soroko, Kara M, Eschle, Benjamin K, Wilkens, Margaret K, Gokhale, Prafulla C, Giles, Francis, Griffin, Andrew, Brown, Bill, Shapiro, Geoffrey I, Zucconi, Beth E, Cole, Philip A, Lemieux, Madeleine E, French, Christopher A

“…NUT midline carcinoma (NMC) is a rare, aggressive subtype of squamous carcinoma that is driven by the BRD4-NUT fusion oncoprotein. BRD4, a BET protein, binds…”
Get full text

Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model by Iorgulescu, J Bryan, Ruthen, Neil, Ahn, Ryuhjin, Panagioti, Eleni, Gokhale, Prafulla C, Neagu, Martha, Speranza, Maria C, Eschle, Benjamin K, Soroko, Kara M, Piranlioglu, Raziye, Datta, Meenal, Krishnan, Shanmugarajan, Yates, Kathleen B, Baker, Gregory J, Jain, Rakesh K, Suvà, Mario L, Neuberg, Donna, White, Forest M, Chiocca, E Antonio, Freeman, Gordon J, Sharpe, Arlene H, Wu, Catherine J, Reardon, David A

“…The GL261 and CT2A syngeneic tumor lines are frequently used as immunocompetent orthotopic mouse models of human glioblastoma (huGBM) but demonstrate distinct…”
Get full text

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma by Ananthapadmanabhan, Varsha, Frost, Thomas C, Soroko, Kara M, Knott, Aine, Magliozzi, Brianna J, Gokhale, Prafulla C, Tirunagaru, Vijaya G, Doebele, Robert C, DeCaprio, James A

“…Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin with 2 etiologies. Merkel cell polyomavirus (MCPyV) integration is present in…”
Get full text

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma by Iorgulescu, J Bryan, Gokhale, Prafulla C, Speranza, Maria C, Eschle, Benjamin K, Poitras, Michael J, Wilkens, Margaret K, Soroko, Kara M, Chhoeu, Chhayheng, Knott, Aine, Gao, Yan, Lim-Fat, Mary Jane, Baker, Gregory J, Bonal, Dennis M, Nguyen, Quang-Dé, Grant, Gareth R L, Ligon, Keith L, Sorger, Peter K, Chiocca, E Antonio, Anderson, Ana C, Kirschmeier, Paul T, Sharpe, Arlene H, Freeman, Gordon J, Reardon, David A

“…Dexamethasone, a uniquely potent corticosteroid, is frequently administered to patients with brain tumors to decrease tumor-associated edema, but limited data…”
Get full text

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC by Gero, Thomas W., Heppner, David E., Beyett, Tyler S., To, Ciric, Azevedo, Seth C., Jang, Jaebong, Bunnell, Thomas, Feru, Frederic, Li, Zhengnian, Shin, Bo Hee, Soroko, Kara M., Gokhale, Prafulla C., Gray, Nathanael S., Jänne, Pasi A., Eck, Michael J., Scott, David A.

“…[Display omitted] The C797S mutation confers resistance to covalent EGFR inhibitors used in the treatment of lung tumors with the activating L858R mutation…”
Get full text

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer by Köhler, Jens, Zhao, Yutong, Li, Jiaqi, Gokhale, Prafulla C, Tiv, Hong L, Knott, Aine R, Wilkens, Margaret K, Soroko, Kara M, Lin, Mika, Ambrogio, Chiara, Musteanu, Monica, Ogino, Atsuko, Choi, Jihyun, Bahcall, Magda, Bertram, Arrien A, Chambers, Emily S, Paweletz, Cloud P, Bhagwat, Shripad V, Manro, Jason R, Tiu, Ramon V, Jänne, Pasi A

“…gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB…”
Get full text

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer by To, Ciric, Beyett, Tyler S, Jang, Jaebong, Feng, William W, Bahcall, Magda, Haikala, Heidi M, Shin, Bo H, Heppner, David E, Rana, Jaimin K, Leeper, Brittaney A, Soroko, Kara M, Poitras, Michael J, Gokhale, Prafulla C, Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J, Gero, Thomas W, Cameron, Michael D, Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant…”
Get full text

Abstract P203: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines by Ananthapadmanabhan, Varsha, Knott, Aine, Soroko, Kara M., Gokhale, Prafulla C., Tirunagaru, Vijaya, Doebele, Robert, DeCaprio, James A.

“…Abstract Background: MCC is a highly aggressive neuroendocrine carcinoma of the skin with a poor overall prognosis. Current treatment options include surgery…”
Get full text

Milademetan is a highly potent MDM2 inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC) by Ananthapadmanabhan, Varsha, Frost, Thomas C., Soroko, Kara M., Knott, Aine, Magliozzi, Brianna, Gokhale, Prafulla C., Tirunagaru, Vijaya, Doebele, Robert C., DeCaprio, James A.

Get full text

Establishment of the Bcwm.2 Cell Line As a BTK-Inhibitor Resistant, BCL2 Inhibitor Sensitive in Vitro and In Vivo Study Model for Waldenström's Macroglobulinemia by Liu, Shirong, Liu, Xia, Soroko, Kara M, Canning, Alexa G, Kofides, Amanda, Yusuf, Choudhury Fabliha Binte, Penailillo, Johany, Tsakmaklis, Nickolas, Patterson, Christopher J, Carrasco, Ruben D., Hunter, Zachary R, Gokhale, Prafulla C., Sarosiek, Shayna R, Castillo, Jorge J., Treon, Steven P

“…Background: Waldenström's macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder characterized by bone marrow (BM) infiltration with…”
Get full text

Allosteric inhibition of drug resistant forms of EGFR L858R mutant NSCLC by To, Ciric, Beyett, Tyler S., Jang, Jaebong, Feng, William W., Bahcall, Magda, Haikala, Heidi M., Shin, Bo H., Heppner, David E., Rana, Jaimin K., Leeper, Brittaney A., Soroko, Kara M., Poitras, Michael J., Gokhale, Prafulla C., Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J., Gero, Thomas W., Cameron, Michael D., Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A., Eck, Michael J., Gray, Nathanael S., Jänne, Pasi A.

“…Although treatment with small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is initially efficacious for patients with…”
Get full text